A Prospective Randomized Controlled Multicenter Study of the Effect of Dalteparin on Quality of Life in Unresectable Pancreatic Cancer.
Phase of Trial: Phase III
Latest Information Update: 17 Oct 2015
At a glance
- Drugs Dalteparin sodium (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer; Thromboembolism
- Focus Therapeutic Use
- 04 Mar 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Feb 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Feb 2013 Planned end date (Sep 2014) added as reported by ClinicalTrials.gov.